(2R,3R,4R)-4-amino-1,1,1,3-tetrafluoro-4-(2-fluorophenyl)pentan-2-ol | 1432511-89-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3R,4R)-4-amino-1,1,1,3-tetrafluoro-4-(2-fluorophenyl)pentan-2-ol
• CAS: 1432511-89-1
• 化学式: C₁₁H₁₂F₅NO
• 分子量: 269.214
• InChiKey: VTVBQNYESQGTTR-IVZWLZJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R)-4-amino-1,1,1,3-tetrafluoro-4-(2-fluorophenyl)pentan-2-ol 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 硝酸 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 (4R,5R,6R)-4-(5-amino-2-fluorophenyl)-5-fluoro-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine
  参考文献：
  名称：

  β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease

  摘要：

  An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pK(a) and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF A beta 40 and 42 in rats at oral doses as low as 1 mg/kg. The effect was long lasting, showing a significant reduction of A beta 40 and 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.

  DOI：

  10.1021/jm400225m
• 作为产物：
  描述：

  2'-氟苯乙酮 在 盐酸 、 titanium(IV) tetraethanolate 、 四丁基氟化铵 、 二异丁基氢化铝 、 copper(l) chloride 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 2.5h， 生成 (2R,3R,4R)-4-amino-1,1,1,3-tetrafluoro-4-(2-fluorophenyl)pentan-2-ol
  参考文献：
  名称：

  β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease

  摘要：

  An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pK(a) and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF A beta 40 and 42 in rats at oral doses as low as 1 mg/kg. The effect was long lasting, showing a significant reduction of A beta 40 and 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.

  DOI：

  10.1021/jm400225m

文献信息

• [EN] FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS<br/>[FR] FLUORO- [1,3] OXAZINES SERVANT D'INHIBITEURS DE LA BACE1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014114532A1

  公开（公告）日：2014-07-31

  The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

  本发明提供了具有BACE1抑制活性的化合物I的化合物，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病等疾病方面是有用的。
• FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS
  申请人：WOLTERING Thomas

  公开号：US20150376172A1

  公开（公告）日：2015-12-31

  The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

  本发明提供一种具有BACE1抑制活性的I型化合物，其制造方法，包含它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防阿尔茨海默病等疾病方面非常有用。